Liraglutide Injection Shortage: Victoza Supply Limited While Saxenda Remains Available

What’s in Shortage

Liraglutide injection, a medication used in the therapeutic category of Endocrinology and Metabolism, is currently listed on the FDA drug shortage database. The shortage specifically impacts certain presentations of the medication, including the brand name Victoza. The dosage form affected is the 6 mg/1 mL injection.

This shortage was first posted on July 18, 2023, and was most recently updated on February 1, 2026.

Which Manufacturers Are Affected

Novo Nordisk, Inc. is the primary manufacturer for these products. The availability status varies by specific product and NDC number:

• Victoza (Liraglutide) Injection, 6 mg/1 mL (NDC 0169-4060-12 and 0169-4060-13): Limited Availability. The estimated duration for this shortage is currently to be determined (TBD).
• Saxenda (Liraglutide) Injection, 6 mg/1 mL (NDC 0169-2800-15): Available.
• Liraglutide Injection, 6 mg/1 mL (NDC 0480-3667-22 and 0480-3667-20): Available (Distributed by Teva).

Patients or healthcare providers seeking more information can contact Novo Nordisk, Inc. at 833-493-4689.

Why There’s a Shortage

The FDA source data does not provide a specific reason for the limited availability of Victoza at this time.

What Patients Should Do

If you are currently prescribed Victoza or another form of Liraglutide, please consider the following steps:

• Consult your healthcare provider: Discuss your treatment plan and any concerns regarding medication availability. Do not make changes to your medication regimen without professional medical guidance.
• Speak with your pharmacist: Your pharmacist can provide the most current information on local stock levels and potential fulfillment timelines.
• Contact the manufacturer: You may reach out to Novo Nordisk at 833-493-4689 for updates on supply status.

Source

Information provided by the FDA Drug Shortage Database.